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EDITORIAL
BLOOD PLATELETS

REWARDING experiences with the blood platelets have been the fruit of multiple
disciplinary talents devoted to understanding these, the least of the formed elements
of the blood." In 1882 Bizzozero' not only described the platelets but demonstrated
their part in the coagulation of the blood, their adhesiveness, even their participation
in thrombi. The succeeding decades were marked, platelet-wise, by Wright's'" discovery (1906) that the platelets were the shed cytoplasmic fragments of the megakaryocytes of the marrow; by Tocantins'"^ (1938) masterly updating of the literature
in the same year that Michels performed a similar monumental service for the mast
cells, and by the scholarly but almost unnoticed monograph of Fonio" (1942).
Although sharpening methodology and increasing complexity of instrumentation were the accidental bases of the new platelet experiences, elucidation and stabilization of one after the other of the plasma and serum clotting factors^"-^' were the
prerequisites for appreciating the dynamic transformations of the platelets themselves in the flooding, transient medium which forms their environment. That worthwhile stability of the coagulation factor system has been nearly attained, if only for
present platelet purposes, is evidenced by the identification of the new and at once
powerful prothrombin activator and prothrombin derivative (autoprothrombin C)
with factor X.'»
With transformational possibilities recognized and non-transforming media available, the ultrastructure of the platelet revealed a protoplasm bounded by a membrane
60 Angstrom units thick and apparently plain in contour, although segmental interruption of this membrane becomes apparent very early in clotting. Within the platelet
and against a cytoplasmic matrix containing poorly defined densities are four well
defined structures: among 50 to 100 granules, the common round or oval granules
of considerable density predominate (granulomere alpha); next appear a few small
mitochondria (granulomere beta); microvesicles and tubuli (granulomere gamma);
and, finally granules with clear interiors (granulomere delta).
Concurrent physiologic studies added increasing numbers of platelet factors (listed
by arable numerals) to the clotting scheme."'^'' Platelet factor 1 is an accelerator of
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prothrombin conversion to thrombin and is known to be platelet-adsorbed plasma
factor V. Platelet factor 2 aids in the interaction of thrombin and fibrinogen. Platelet
factor 3 has the triple role of synergism with coagulation factor V l l l to catalyse the
conversion of prothrombin to thrombin, with plasma factor I X to function similarly
and of facilitating the conversion of prothrombin to plasma factor V I I . Platelet factor
4 neutralizes the activity of heparin. Platelet factor 5 is a clottable factor, platelet
factor 6 an antifibrinolysin and platelet factor 7 a cothromboplastin. In addition
there can be found histamine,'" serotonin, contractile protein, ATP, fibrinolysin activity,^" a platelet procoagulant inhibitor and an inactivator of plasma factor V. An
endothelial supporting role has long been manifest. Even the unused, disintegrating
platelet is an important source of plasma lipids." The stickiness of the platelet
originally noted was soon found to be crucial in hemostasis for adhesion to injured
vascular linings and for formation of the platelet plug. Under the light microscope,
platelet fusion became known as the phenomenon of viscous metamorphosis. Without
platelets, clot retraction was found to fail. Furthermore platelets were demonstrated
to have a surprisingly active metabolism aimed especially at the preparation of high
energy bonds.
With this background, function gradually became related to structure. Johnson
and her associates'^ obtained granules about 350 mM in diameter with platelet factor
3 activity from platelets treated in a sonic oscillator. Schulz, Jurgens and Hiepler^'
related platelet factor 3 activity and platelet factor 1 activity similarly to the common
dense granules. Platelet factor 1 activity was also associated with the mitochondria
and microvesicles, but platelet factors 2 and 4 were associated with the hyalomere.
Fixed but timed electron-microscopic studies revealed far-reaching ultrastructural transformations further related to platelet function. As seen in electron micrographs, platelets in their normal circulating status were disk-like and electron opaque
but soon after venipuncture, if clotting was slowed for their study, they rapidly
protruded long, sticky dendritic processes. At this pseudopodial stage they quickly
aggregated in the various stages of viscous metamorphosis. Study of the relatively
few platelets persisting unaggregated, revealed further transformation leading to
spreading of the hyalomere between the platelet processes accompanied by loss of
much of the central granular content.^'""''^'^^
Similar sequential electron micrographs of sectioned early phase clotting related
fibrin to the tridimensional process and permitted interior observation of the larger
platelet aggregates.^' In such sections the individual platelets, at first round or oval,
put out short, stubby projections. The outer membrane, single and originally dense,
became segmentally interrupted. As time elapsed the projections became more and
more numerous and elongated, the limiting membrane was once more sharply defined and the granules became centrally concentrated. At this stage a few fibrin
strands appeared and the platelets began to fit together like the pieces of a jig-saw
puzzle. With small aggregates formed, membranes were still intact, separated by a
space a few hundred Angstroms in width. Fibrin was apparent between most of the
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platelets, closely opposed to the surface of some and a great distance from others.
As the filmly clot became macroscopically visible, micrographs revealed larger and
more complex platelet aggregates until single platelets were rare and fibrin was deposited in larger and larger amounts. The larger platelet aggregates were of two types:
the first with easily identifiable platelet limiting membranes presented specifically
recognizable granulomeres; the second large aggregate type, increasingly apparent
in the retracting clot, showed absence of identifiable membranes in their interiors
and poorly defined granular material, while peripherally there were sac-like protrusions
containing finely granular material and microvesicles. Schulz, Jurgens and Hiepler^'
noted that the common dense granules emerged from the platelets at the beginning
of clotting. Bloom'-* and Aleksandrowicz^ noted that when the granules from the
chromomere had been released from the platelets, numerous small empty, round
spaces were left. Sequential section micrographs of the clotting process emphasizing granular changes" revealed progressive loss of the common dense granules, on
the average to 40 per cent of the original number, indeed some platelets became virtually empty of granules and contained only hyaloplasm. When fibrin was related to
more intact platelets, a crescentic gathering of the granules along the surface adjacent
to the fibrin took place. Membrane defects appeared and in some areas of the clot
there was dense intermingling of fibrin strands, platelet debris and free granules.
The number of vesicles also decreased during viscous metamorphosis.
When the entire clotting process was examined by sectioning and staining the
normal platelet-plasma clot for light microscopy step-wise from its incipiency through
final retraction, remarkable insight into platelet-fibrin relationships was obtained."''°
The platelets enlarged, sent out pseudopodial process and joined to form larger and
larger aggregates. Normal fibrin patterns were remarkably geometric in configuration.
The platelet aggregates acted as focal points for the construction of a coarse fibrin
lattice, the coarse fibrin strands connecting one group of platelets with all neighboring
groups as the major structure. In the intervening spaces in addition there was a fine
fibrin network. The dendritic process of the platelet aggregates extended into the
fibrin nets joining the appendages of other platelet masses producing a platelet lattice
overlying the fibrin. Indeed after fibrinolysin, the fibrin networks, both fine and
coarse, were gone but the cast of the platelet network remained. Poole^' has properly
emphasized the more static nature of the clot and the churning environment of the
thrombus, however his electron micrographs revealed that the apparently structureless
areas of the thrombus studied under the light microscope were again composed of
interdigitating, closely packed platelets.
Of very particular importance has been the realization that each and every
functional facet of the platelet has been disclosed as a source of platelet disease
when functional failure ensued. Braunsteiner and his associates''^" described the first
of a long series of hemorrhagic diseases attributable to intrinsic platelet abnormalities
in their dehneation of thrombocytoasthenia, a constitutional disease in which ultrastructural studies demonstrated the inability of platelets from such patients to extend
pseudopodial process. Next platelet aggregation failed and clot retraction was impeded. Fibrin attachment, when it occurred, was to single platelets, not aggregates.
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Gross'' found that clot retraction and platelet transformation were dependent on a
high energy potential in platelets with ATP as the main source of that energy. In
patients with thrombocytoasthenia he further uncovered hereditary platelet defects
in two glycolytic enzymes: glyceraldehyde phosphate dehydrogenase and pyruvate
kinase, ths lack of the former being largely responsible for the diminution of ATP
in the affected platelets.
Subsequently, a number of additional secondary thrombocytoasthenias with
platelets similarly affected by impairment of process formation and aggregation have
been reported in leukemia, tuberculosis, pernicious anemia and other conditions,
although their metabolic faults have not as yet been delineated.""
Braunsteiner, Riddle, Johnson and their associates'"-" "'^' demonstrated a second
important group of qualitative platelet diseases in which platelet numbers and coagulation factors were again normal but in which platelet factor 3 activity was deficient.
Uitrastructurally the platelets spread excessively within fixed time limits but they were
unable to release their granular chromomeres. Platelet factor 3 activity of such platelets could be restored to normal in the test tube by sonic oscillation." Secondary
thrombocytopathies, differing in one or more respects from the idopathic group have
already been reported in sprue, scurvy and in some cases of uremia." Hemmeler"
recently reported an ultrastructural famihal variant in which platelet sections presented abnormally large platelets with greatly diminished granule numbers and low
granule density.
Distorted platelet-fibrin relationships leading to sparse, defective fibrin networks
have now been described in thrombocytoasthenia,
platelet clottable factor deficiency,
polycythemia vera and macroglobulinemia of Waldenstrom.""
The latter condition
underlines the concept of extrinsic platelet abnormalities in contrast to the intrinsic
forms previously considered. Non-specific coating of the platelets with the monstrous
polymers of globulins in patients with macroglobulinemia leads to abnormal bleeding
by preventing dendritic process formation and interfering with normal platelet-fibrin
relationships.^"'^^ Platelets of normal persons are similarly affected when exposed to
macroglobulins in vitro.
Immunologic thrombocytopenic puipura (ITP) dramatically demonstrated by
Harrington and co-workers" to be caused by anti-platelet antibodies is still another
example of extrinsically produced thrombocytoasthenia. In this condition specific
attachment of anti-platelet antibody to the platelet antigens leads to pseudopodial
deficiency over and above the well known reduction in platelet numbers."" Recent
improvements in the methodology of anti-platelet antibody detection especially the
production of increased test platelet membrane permeability induced by cathode irradiation" and the preparation of control serum in an equivalent thrombocytopenic
milieu^' have further improved the reproducibilty of this important procedure. Utilization of fluorescein labeled antiglobulin serum revealed its affinity for the megakaryocytes in the marrows of patients with chronic ITP to be of a non-gamma
globulin nature but indicating adherence of a humoral substance to megakaryocytes
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in this condition.'* Cr" labeling for measuring platelet life-span has shown that thrombocytopenic states belong to three broad categories: primary producion deficit, predominant production deficit and predominant perpheral destruction.. However, in
20 per cent of the cases of chronic ITP so studied, a dual mechanism of peripheral
destruction and production deficit was operative."
Time relationships of platelets are being recognized for their true value in respect
to the transiency of their origins and functions. Schulman" in a painstaking study
of a thrombocytopenia due to an amegakaryocytic marrow whish responds to plasma
injections by manifestations of megakaryocytopoiesis and thrombocytopoiesis has
timed the human platelet cycle with reproducible rises in platelet counts to 700,000
platelets per cu. mm. ten days after each plasma transfusion with returns to previous
thrombocytopenic levels in three weeks. Platelet survival times must be thought of
both in terms of platelet survival in storage in vUro and platelet survival in the transfused recipient in vivo. These important concepts have been ably covered in the
formative years of this journal and to such pages the reader is referred. For our
present purpose a few observations will suffice. Transfusion therapy with ACD
banked blood stored at 4 C. for more than 24 hours may lead to the loss-dilution
syndrome" of hemorrhage from low platelet levels since viable platelet levels in stored
blood fall appreciably after three hours of such storage and precipitously after 24
hours of storage. The continued administration of small amounts of similarly banked
bloods over periods of days or weeks does not lead to dilution thrombocytopenia
but may eventuate in the stimulation of anti-platelet antibody formation on the part
of the persistent recipient. The blood platelets of man survive in his own blood
stream, if not put to use, for from eight to 14 days." However, removed from his
body, maximum storage of platelet-rich plasma is ten hours and that of concentrates
is four hours if loss of less than 50 per cent of transfused platelets is to be achieved."
Stored platelets thus lose their ability to survive in direct proportion to their storage
time." Here, extended survival times for viable platelet storage as glycerolized
frozen platelets' leave a loop-hole for the future. Fresh platelets transfused into
thrombocytopenic recipients survive normally providing there is no thrombocytolytic
factor in the recipient and providing the recipient is not undergoing excessive hemorrhage." Transfused platelets may survive only a matter of a few minutes or hours
in recipients with circulating anti-platelet antibodies or in recipients suffering from
undue bleeding who lose not only large numbers of their own platelets but their
borrowed ones as well. It should be cautioned that low platelet survival in the recipient could also mean effective and proper utilization in hemostasis at the focal
bleeding sites precluding further circulation for the sole purpose of being counted.

The future of the blood platelets promises to be exciting in the areas of: concurrent complexities of platelet dysfunctions plus plasma or serum coagulation factor
deficiencies; more effective transfusions of viable platelet suspensions; and appropriate platelet substitutes. Recalling the long list of platelet functions it would only
be fair to demand of the pioneer platelet substitutes the performance of one platelet
activity at a time to avoid the disappoinment of failed simulation of a megakaryo381
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cytic extrusion that is at once transport, trephone
—lohn W. Rebuck, M.D., Ph.D., The Henry Ford

and hemostatic
Hospital.

constellation.
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